下调和上调
BCL6公司
癌症研究
细胞生长
长非编码RNA
肝细胞癌
癌基因
细胞
生物
小RNA
竞争性内源性RNA
化学
细胞周期
免疫学
基因
B细胞
生发中心
遗传学
抗体
生物化学
作者
Hongyan Ding,Juan He,Weili Xiao,Zhihong Ren,Wanting Gao
标识
DOI:10.1615/critreveukaryotgeneexpr.2022039954
摘要
Long noncoding RNA (lncRNA) PCED1B-AS1 has been characterized as an oncogene in glioma, but its role in hepatocellular carcinoma (HCC) is unknown. We explored the involvement of PCED1B-AS1 in HCC. Its expression in paired HCC and nontumor tissues from 62 HCC patients was determined by qRT-PCR. Correlations of PCED1B-AS1 with miR-10a and BCL6 were analyzed by Pearson's correlation coefficient. The patients were followed up for 5 years to analyze the prognostic value of PCED1B-AS1 for HCC. Interactions among PCED1B-AS1, miR-10a, and BCL6 were detected by overexpression experiments. Cell proliferation was analyzed by CCK-8 assay. We found the following. PCED1B-AS1 is upregulated in HCC, and its upregulation correlates with poor survival. Across HCC tissues, PCED1B-AS1 expression inversely correlates with miR-10a but positively correlates with BCL6. In HCC cells, overexpression of PCED1B-AS1 decreases miR-10a expression and increases BCL6 expression. Moreover, PCED1B-AS1 overexpression reduces the inhibitory effects of miR-10a overexpression on BCL6 expression and cell proliferation. PCED1B-AS1 is upregulated in HCC and regulates the miR-10a/BCL6 axis to promote cell proliferation.
科研通智能强力驱动
Strongly Powered by AbleSci AI